Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|September 21, 2021
Daily Medication Pearl: Zegalogue (Dasiglucagon) for Severe Hypoglycemia
Author(s)Saro Arakelians, PharmD
Dasiglucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.
Advertisement
Medication Pearl of the Day: Zegalogue (dasiglucagon)
Indication: Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Insight:
- Dasiglucagon autoinjector and prefilled syringe are for subcutaneous injection only.
- Dosing: The dose in adults and pediatric patients aged 6 years and older is 0.6 mg.
- Dosage forms: Dasiglucagon comes in 0.6 mg/0.6 mL single-dose autoinjector and 0.6 mg/0.6 mL single-dose prefilled syringe.
- Adverse events: Most common adverse events seen from dasiglucagon include nausea, vomiting, headache, diarrhea, and injection site pain.
- Mechanism of action: Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
- Interactions: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. In patients taking indomethacin, dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia. In patients taking Warfarin, dasiglucagon may increase the anticoagulant effect of warfarin.
- Manufacturer: Zealand Pharma
Sources:
Advertisement
Related to this article
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5